Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study

Transplantation Proceedings
X ZhuY Le

Abstract

Hyperuricemia and posttransplantation erythrocytosis (PTE) are frequent complications after kidney transplantation and are important risk factors for cardiovascular events. Losartan decreases serum uric acid and hemoglobin (Hb) concentrations and may be a useful agent for treatment of hyperuricemia and PTE. To evaluate the influence of losartan on serum creatinine (SCr), serum uric acid, and hemoglobin (Hb) concentrations in patients after kidney transplantation and to evaluate the safety profile of losartan in these patients. Sixty-six Han Chinese patients (43 men and 23 women; mean [SD] age, 40.45 [11.50] years) were enrolled in the study. All patients had undergone a first cadaveric donor kidney transplantation at least 3 months previously and had stable graft function with SCr concentration less than 176.8 micromol/L and Hb concentration greater than 110 g/L. The patients were divided into 2 groups (losartan group, n = 34; and control group, n = 32) according to the odevity of patient identification number. Patients in the losartan group received losartan, 50 mg/d; patients in the control group did not receive losartan. Each patient was followed up for 6 months. Nine patients in the losartan group and 5 patients in the cont...Continue Reading

References

Mar 29, 2001·Journal of the American Society of Nephrology : JASN·Pablo IñigoFrancisca Rivera
May 1, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·A SchmidtG Mayer
Sep 7, 2001·Transplantation·A L Kamper, A H Nielsen
Mar 6, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Angela Yee Moon WangSiu Fai Lui
Mar 13, 2003·Kidney International·Demetrios V VlahakosNicolaos E Madias
May 22, 2003·Annals of the Rheumatic Diseases·T Bardin
Jan 25, 2006·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Richard N FormicaMargaret J Bia
Nov 14, 2006·Transplantation Proceedings·A AndrésUNKNOWN Valsartan in Renal Transplantation Group
Jan 18, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·L TylickiB Rutkowski
Mar 14, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Kim T SinnamonDamian G Fogarty
Sep 12, 2007·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·S HiremathG A Knoll

❮ Previous
Next ❯

Citations

Mar 13, 2014·Nature Reviews. Rheumatology·Frances ReesMichael Doherty
Oct 1, 2015·Expert Opinion on Therapeutic Targets·Dan-Qin SunMing-Hua Zheng
May 31, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Anna PisanoCarmine Zoccali

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.